Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1987 Jun;71(6):415–417. doi: 10.1136/bjo.71.6.415

Cyclosporin therapy in Mooren's ulcer.

D Wakefield, L P Robinson
PMCID: PMC1041189  PMID: 3620420

Abstract

Mooren's ulcer is a rare disease of presumed autoimmune aetiology. Some cases run a chronic severe course and fail to respond to local and systemic therapy. We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy. Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests. All these resolved on reducing the dosage of cyclosporin. The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.

Full text

PDF
415

Images in this article

416Image
on p.416

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown S. I., Mondino B. J., Rabin B. S. Autoimmune phenomenon in Mooren's ulcer. Am J Ophthalmol. 1976 Dec;82(6):835–840. doi: 10.1016/0002-9394(76)90058-1. [DOI] [PubMed] [Google Scholar]
  2. Foster C. S. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980 Feb;87(2):140–150. doi: 10.1016/s0161-6420(80)35272-x. [DOI] [PubMed] [Google Scholar]
  3. Mondino B. J., Brown S. I., Rabin B. S. Autoimmune phenomena of the external eye. Ophthalmology. 1978 Aug;85(8):801–817. doi: 10.1016/s0161-6420(78)35618-9. [DOI] [PubMed] [Google Scholar]
  4. Mondino B. J., Brown S. I., Rabin B. S. Cellular immunity in Mooren's ulcer. Am J Ophthalmol. 1978 Jun;85(6):788–791. doi: 10.1016/s0002-9394(14)78106-1. [DOI] [PubMed] [Google Scholar]
  5. Murray P. I., Rahi A. H. Pathogenesis of Mooren's ulcer: some new concepts. Br J Ophthalmol. 1984 Mar;68(3):182–187. doi: 10.1136/bjo.68.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nussenblatt R. B., Palestine A. G., Chan C. C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275–282. doi: 10.1016/s0002-9394(14)77814-6. [DOI] [PubMed] [Google Scholar]
  7. Percutaneous transluminal coronary angioplasty. Lancet. 1979 Aug 4;2(8136):235–236. [PubMed] [Google Scholar]
  8. Schaap O. L., Feltkamp T. E., Breebaart A. C. Circulating antibodies to corneal tissue in a patient suffering from Mooren's ulcer (ulcus rodens corneae). Clin Exp Immunol. 1969 Oct;5(4):365–370. [PMC free article] [PubMed] [Google Scholar]
  9. Shevach E. M. The effects of cyclosporin A on the immune system. Annu Rev Immunol. 1985;3:397–423. doi: 10.1146/annurev.iy.03.040185.002145. [DOI] [PubMed] [Google Scholar]
  10. Strom T. B., Loertscher R. Cyclosporin-induced nephrotoxicity. Inevitable and intractable? N Engl J Med. 1984 Sep 13;311(11):728–729. doi: 10.1056/NEJM198409133111109. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES